To characterize the treatment patterns and survival outcomes of sarcomatoid bladder cancer, a rare urothelial variant histology using a large population level cancer database.
The National Cancer Database was queried for all cases of sarcomatoid bladder cancer using International Classification of Disease-O-3 morphologic code 8122 between 2004 and 2014. Primary outcome was overall survival.
A total of 489 patients met our inclusion criteria and were included in our analysis. Average age at diagnosis was 70.4 years. The majority of the population was male (61.8%) and Caucasian (92.2%). Tumor characteristics included 23.7% cT1, 41.1% cT2 and 15.3% cT3 or above. Median overall survival was 18.4 months (95% CI 13.3-23.6). On multivariate Cox proportional analysis, radical cystectomy alone or with multimodal therapy (chemotherapy or radiotherapy) resulted in a statistically significant reduction in the risk of death as compared to bladder preservation surgery alone. Survival in the radical cystectomy group did not differ between radical cystectomy alone and those receiving either neoadjuvant or adjuvant chemotherapy.
Sarcomatoid bladder cancer has poor prognosis with 18.4-month median overall survival. While our data suggest that aggressive treatment improves outcomes, the role of multimodal therapy is unclear. Future study should continue to focus on multi-institutional collaboration to determine the most effective therapy.
World journal of urology. 2016 Nov 01 [Epub ahead of print]
Wilson Sui, Justin T Matulay, Ifeanyi C Onyeji, Marissa C Theofanides, Maxwell B James, Arindam RoyChoudhury, Sven Wenske, G Joel DeCastro
Department of Urology, Columbia University Medical Center, Herbert Irving Pavilion, 161 Fort Washington, 11th Floor, New York, NY, 10032, USA. ., Department of Urology, Columbia University Medical Center, Herbert Irving Pavilion, 161 Fort Washington, 11th Floor, New York, NY, 10032, USA., Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, USA.